Gyre Therapeutics, Inc. Increase (Decrease) in Notes Receivables
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Notes Receivables of -$5.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesReceivables · last filed 2026-08-07
- Gyre Therapeutics, Inc. increase (decrease) in notes receivables for the quarter ending 2026-06-30 was -$3.47M.
- Gyre Therapeutics, Inc. increase (decrease) in notes receivables for the quarter ending 2026-03-31 was -$1.90M.
- Gyre Therapeutics, Inc. increase (decrease) in notes receivables for the quarter ending 2025-12-31 was $4.85M, a 12.07% increase year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in notes receivables for the quarter ending 2025-09-30 was $178.00K.
- Gyre Therapeutics, Inc. increase (decrease) in notes receivables for fiscal 2025 was $1.15M, a 71.52% decline from fiscal 2024.
- Gyre Therapeutics, Inc. increase (decrease) in notes receivables for fiscal 2024 was $4.03M.
- Gyre Therapeutics, Inc. increase (decrease) in notes receivables for fiscal 2023 was -$1.11M.
| Period end | Increase (Decrease) in Notes Receivables 3 month | Increase (Decrease) in Notes Receivables 6 month | Increase (Decrease) in Notes Receivables 9 month | Increase (Decrease) in Notes Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$5.37M 10-Q · filed 2026-08-07 | -$526.00K derived: sum of 3 quarters · filed 2026-08-07 | -$348.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$1.90M 10-Q · filed 2026-05-08 | $2.95M derived: sum of 2 quarters · filed 2026-05-08 | $3.12M derived: sum of 3 quarters · filed 2026-05-08 | $1.49M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $5.03M derived: sum of 2 quarters · filed 2026-03-13 | $3.39M derived: sum of 3 quarters · filed 2026-08-07 | $1.15M 10-K · filed 2026-03-13 |
| 2025-09-30 | $178.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.46M derived: sum of 2 quarters · filed 2026-08-07 | -$3.70M 10-Q · filed 2025-11-07 | $625.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$3.88M 10-Q · filed 2026-08-07 | $447.00K derived: sum of 3 quarters · filed 2026-08-07 | $233.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$2.24M 10-Q · filed 2026-05-08 | $2.08M derived: sum of 2 quarters · filed 2026-05-08 | $1.87M derived: sum of 3 quarters · filed 2026-05-08 | $1.82M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $4.11M derived: sum of 2 quarters · filed 2026-03-13 | $4.06M derived: sum of 3 quarters · filed 2026-03-13 | $4.03M 10-K · filed 2026-03-13 |
| 2024-09-30 | -$214.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$266.00K derived: sum of 2 quarters · filed 2025-11-07 | -$298.00K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$84.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$32.00K 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$1.11M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |